PRODUCT INFORMATION



Oridonin

Item No. 25665

CAS Registry No.: 28957-04-2

Formal Name: 7,20-epoxy-1α,6β,7α,14R-tetrahydroxy-

kaur-16-en-15-one

Synonym: NSC 250682 MF: $C_{20}H_{28}O_6$ FW: 364.4 **Purity:** ≥98% UV/Vis.: λ_{max} : 238 nm Supplied as: A crystalline solid

Storage: -20°C Stability: ≥2 years

Н `H OH

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Oridonin is supplied as a crystalline solid. A stock solution may be made by dissolving the oridonin in the solvent of choice. Oridonin is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of oridonin in ethanol is approximately 20 mg/ml and approximately 30 mg/ml in DMSO and DMF.

Oridonin is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, oridonin should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Oridonin has a solubility of approximately 0.1 mg/ml in a 1:9 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Oridonin is a diterpenoid that has been found in R. rubescens and has anti-inflammatory and anticancer properties. 1,2 It is an inhibitor of AKT1 and AKT2 (IC $_{50}$ s = 8.4 and 8.9 μ M, respectively). 1 Oridonin inhibits proliferation of KYSE70, KYSE410, and KYSE450 esophageal cancer cells in a dose-dependent manner, halts the cell cycle at the G_2/M phase, and induces apoptosis when used at a concentration of 20 μ M. It decreases the expression of cleaved poly(ADP-ribose) polymerase (PARP), caspase-3, caspase-7, and Bime and the protein levels of phosphorylated AKT and reduces AKT activity. Oridonin reduces tumor growth in patient-derived mouse tumor models when administered at doses of 40 and 160 mg/kg. Oridonin is also an inhibitor of NLRP3 inflammasome assembly and activation.² It inhibits inflammation in wild-type, but not NIrp3-/-, mice in a model of high-fat diet-induced type 2 diabetes when administered at a dose of 3 mg/kg.

References

- 1. Song, M., Liu, X., Liu, K., et al. Targeting AKT with oridonin inhibits growth of esophageal squamous cell carcinoma in vitro and patient-derived xenografts in vivo. Mol. Cancer. Ther. 17(7), 1540-1553 (2018).
- 2. He, H., Jiang, H., Chen, Y., et al. Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nat. Commun. 9(1):2550 (2018).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information Buyer agrees to purchase the mater can be found on our website.

Copyright Cayman Chemical Company, 10/11/2018

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM